aoyixin limertinib tablets lung cancer 80mg

Description

Indication & Scope

AoYiXin® Limertinib Tablets treats locally advanced or metastatic non-small cell lung cancer with EGFR T790M mutation positivity, as well as first-line treatment for non-small cell lung cancer carrying EGFR exon 19 deletion or exon 21 L858R sensitizing mutations.

Mechanism: It irreversibly binds to and inhibits mutated EGFR tyrosine kinase, blocks the downstream RAS/RAF/MEK/ERK signal transduction pathway, and suppresses the proliferation of tumor cells driven by EGFR mutations.
Drug class: Third-generation oral EGFR tyrosine kinase inhibitor, targeted anti-tumor prescription medicine.
Clinical use: Serves as second-line treatment for EGFR-TKI resistant non-small cell lung cancer with T790M mutation, and first-line targeted therapy for patients with EGFR sensitizing mutation positive non-small cell lung cancer.

Specification

Generic Name	Limertinib Tablets
Brand Name	AoYiXin
Ingredient	Limertinib Tablets
Dosage Form	Tablets
Package	80mg*20 tablets/box
Conditions Treated	Locally advanced and metastatic non-small cell lung cancer with EGFR gene mutations
Taboos	Patients with severe hypersensitivity to limertinib or any auxiliary ingredients of the preparation; pregnant women due to the risk of embryo and fetal toxicity
Place of origin	China
Prescription type	Prescription-only
Storage Conditions	Store at a temperature not higher than 25°C, seal the container to avoid light and moisture
Manufacturer	AoSaiKang Pharmaceutical, Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	H20250004
Approval Date	Jan 14, 2025
Shelf Life	36 months

How to use ?

Recommended Dose: 80mg twice a day for first-line treatment, and 160mg twice a day for second-line T790M mutation treatment.

Time: The two daily doses are taken at an interval of 12 hours, and continuous medication is maintained until disease progression or intolerable adverse reactions occur.

Instructions for use: First-line treatment can be taken with or without food; second-line treatment needs to be taken on an empty stomach, 1 hour before meals or 2 hours after meals. The tablets shall be swallowed whole without crushing or chewing.

Interaction: Strong CYP3A4 inhibitors will increase the blood concentration of limertinib, while strong CYP3A4 inducers will reduce its therapeutic effect, and combined use should be avoided.

Side effects: Diarrhea, dry skin, paronychia, stomatitis, elevated liver transaminase levels, rare interstitial lung disease, and QT interval prolongation.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support